Since some cancer cells strategically enhance their survival by improving the expression of BCL‐xL, new versions of BH3‐mimetics such as A‐1155463 and A‐1331852 have been developed to specifically target BCL‐xL [73, 74]. Here, BCL2L1 is linked to cancer.